Navigation Links
Watson Reaches Settlement with Teva Over Seasonale(R)
Date:5/7/2010

234';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.watson.com/">http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance.  Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31,2009.  Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Confirms EVISTA(R) Patent Challenge
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
3. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
4. Watson Confirms Trilipix(R) Patent Challenge
5. Watson Confirms Rapamune(R) Patent Challenge
6. Watson Confirms Cenestin(R) Patent Challenge
7. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
8. Watson to Present at Barclays 2010 Global Healthcare Conference
9. Watson Receives FDA Approval for Generic Cardizem(R) LA
10. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
11. Watson Announces Actos(R) Patent Challenge Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: ... injectable drug delivery systems, today announced that its Chairman ... present at the Piper Jaffray 26th Annual Healthcare Conference ... EST on Tuesday, December 2, 2014. ... as a "live" listen only Webcast. To listen, please ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... -- Cylene Pharmaceuticals, Inc. has been selected to ... at the 52nd Annual Meeting of the American Society of ... FL, the company announced today.  Kenna Anderes, VP Cancer Biology ... kinase that is essential for the progression of multiple myeloma ...
... 2010 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... first time at the 52nd Annual Meeting of ... activity, safety and tolerability of perifosine in patients ... lymphoma (HL).  KRX-0401 (perifosine) is the Company,s novel, ...
Cached Medicine Technology:Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 2Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 4Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 5
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... 27, 2014 Dr. Ronald Receveur, who has ... a few oral health tips before patients dig into the ... and New Albany affordable cosmetic dentistry, and his ... starch and sugar. While the staff wishes everyone a happy ... for how patients can enjoy a feast that is also ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
(Date:11/27/2014)... 27, 2014 Allowing children to help with ... school, helps give children responsibility, ownership, boosts self-esteem, and above ... , Now, the real question is, how do you encourage ... According to a study published by Child Development Journal, there ... dramatic effect on a child’s willingness to lend a hand. ...
(Date:11/27/2014)... November 27, 2014 "The uglier, the better," ... of December is full of laughter as we enjoy the ... by making a sweater from scratch. " It was a ... and if that weren't ridiculous enough, the Christmas balls were ... , For those interested in participating this year, it's simple ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
... By Randy Dotinga HealthDay Reporter , ... that they,ve successfully implanted "biosynthetic" corneas in 10 patients, ... those with cornea-related vision problems. "The patients, own ... overall improvement in vision," said study co-author May Griffith. ...
... it has filed an Investigational New Drug (IND) application ... to begin a Phase I safety clinical trial for ... cells. This multicenter Phase I safety trial will enroll ... injury patients, with an American Spinal Injury Association (ASIA) ...
... and emotional problems a year after surgery than before their ... key findings of a research study of more than 400 ... . Researchers from The Netherlands spoke to 216 ... who had undergone planned surgery, ranging from plastic surgery to ...
... new surge of scientific research has uncovered telltale signs ... and spinal taps, many questions remain unanswered about the ... of patient care, according to Dr. Kenneth S. Kosik, ... California and co-director of UCSB,s Neuroscience Research Institute. ...
... Massachusetts Medical School have identified a novel approach ... decrease the recurrence of glioblastoma multiforme, the most ... horrendous tumors, and new therapies are desperately needed," ... of biochemistry and molecular pharmacology at the University ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... in cleaning up a massive oil spill off the northwest ... health problems facing workers involved in the recent Deepwater ... the Aug. 24 online issue of the Annals of ...
Cached Medicine News:Health News:Biosynthetic Corneas Show Promise in Transplants 2Health News:Biosynthetic Corneas Show Promise in Transplants 3Health News:Neuralstem files FDA application for first chronic spinal cord injury stem cell trial 2Health News:Neuralstem files FDA application for first chronic spinal cord injury stem cell trial 3Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Are early testing and drug development the most pressing issues in Alzheimer's care? 2Health News:Double-therapy approach effectively inhibited brain cancer recurrence 2Health News:2002 Oil Spill May Shed Light on Health Problems for Deepwater Workers 2Health News:2002 Oil Spill May Shed Light on Health Problems for Deepwater Workers 3
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
... The Ruggles Retractor System, a ... and the versatility of two systems ... hands from the surgical site during ... accurate retractor insertion. The retractor body ...
Fortitude as a unique complement to the spinal concepts family of products....
Medicine Products: